The latest gynaecological cancer news
Updated dose expansion data of the phase I STRO-002-GM1 study were presented today by Ana Oaknin, Principal…
“For patients with stage 1 cervical cancer who are eligible for surgery, radical hysterectomy has…
MIRASOL, an international phase III randomised clinical trial, found that mirvetuximab soravtansine, an antibody and…
Adding the immunotherapy drug pembrolizumab to chemotherapy, with or without bevacizumab, improved overall survival (OS) and…
Researchers at the UNC Gillings School of Global Public Health and UNC Lineberger Comprehensive Cancer…
A new Fred Hutchinson Cancer Center study in the journal Obstetrics & Gynecology investigated how endometriosis, uterine…
Homologous Recombination Deficiency (HRD) is a biomarker that predicts ovarian cancer treatment with PARP inhibitors…
We must urgently increase research funding and awareness of ovarian cancer if we want to…
An innovative cancer drug discovered by scientists at The Institute of Cancer Research, London, UK,…
CU Boulder researchers have discovered a protein’s crucial role in helping breast and ovarian tumours…